Combimatrix (CBMX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Combimatrix (CBMX)

CBMX 6.250

0.0%

Nov 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Lee who started this subject	4/15/2003 10:07:11 PM
From: Paul Lee	Read Replies (1) of 237

CombiMatrix Announces First SARS Virus Microarray BUSINESS WIRE - April 15, 2003 21:08 NEWPORT BEACH, Calif., Apr 15, 2003 (BUSINESS WIRE) -- Acacia Research Corporation (Nasdaq:ACTG)(Nasdaq:CBMX) announced today that CombiMatrix has designed and fabricated the first microarray based on the SARS (Severe Acute Respiratory Syndrome) coronavirus genome published earlier this week. The first microarrays were fabricated within 48 hours of publication of the coronavirus genome sequence believed to be responsible for SARS, underscoring CombiMatrix' ability to rapidly design and build custom microarrays. Researchers at the Centers for Disease Control in Atlanta and at the Michael Smith Genome Sciences Centre in Canada independently announced on Monday that they sequenced the coronavirus genome in an unprecedented 31 days. CombiMatrix technology builds on this momentum by enabling researchers with a fast turnaround custom microarray system. Researchers can now apply this technology to confirm the link between the coronavirus and SARS as well as helping to develop tests to screen for the virus and to develop potential medicines for treating the syndrome. "Our technology platform is ideally suited to taking new genetic sequence information and fabricating a corresponding microarray so researchers and clinicians have a tool for rapid studies," said Dr. Amit Kumar, President and CEO of CombiMatrix. "This SARS chip is designed using the sequence data published this week. We anticipate that researchers will want to make multiple versions of this chip as we learn more about the virus."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next